Asian Transdermal Drug Delivery Systems Market Research Report
- Report Code: TR 1003
- Publish Date: Upcoming
The Asian transdermal drug delivery market, mainly driven by ‘patent cliffs’, increased incidence of chronic diseases, increasing competition, improving patient compliance, reformulation and repositioning of drugs using advanced oral delivery systems, and huge investments made by big pharmaceutical companies, was valued at $1.5 billion in 2013 and is expected to reach $3.0 billion by 2018, at a CAGR of 14.8% from 2013 to 2018.
The report analyzes the market in terms of segments such as active transdermal drug delivery and passive transdermal drug delivery.
The pharmaceutical markets in India and China are growing rapidly, owing to low costs and favorable regulatory environments. The Indian pharmaceutical market was ranked 4th, in terms of volume, and 15th, in terms of value, in 2011. This market is expected to reach $20 billion by 2015. The Chinese pharmaceutical market was ranked third-largest, by value, at $64 billion and is expected to become the second-largest by 2015, with this market being projected to grow at a CAGR of over 20%.
In 2012, Asia held a share of 15.0% in the global drug delivery market and was valued at $21.71 billion. It is projected to grow at a CAGR of 12.6% from 2012 to 2017, to reach $39.35 billion by 2017. The major factors propelling the Asian market include the saturation of the Western markets and the economic downturn in the U.S. and Europe. Furthermore, expansion of the Asian region, increase in disposable incomes, development of healthcare infrastructure, increasing penetration of health insurance, and rising prevalence of chronic diseases are expected to drive the growth of the pharmaceutical market in this region. As a result, the Asian oral drug delivery market is expected to grow significantly during the period under consideration.
The report also provides an extensive competitive landscaping of the leading companies operating in this market. The main companies in the market include Novartis, Johnson & Johnson, 3M Company, and Noven, among others. Furthermore, segment and country-specific company shares, news & deals, M&A, segment-specific pipeline products, product approvals, and product recalls of the major companies have been detailed in this report.
Customization Options:
Along with the market data, customize the MMM assessments to meet your company’s specific needs. Customize to get a comprehensive summary of the industry standards and deep dive analysis of the following parameters:
Product Analysis
- Usage pattern (in-depth trend analysis) of products (segment-wise)
- Product matrix, which gives a detailed comparison of product portfolio of each company, mapped at country and sub-segment levels
- End-user adoption rate analysis of the products (segment-wise and country-wise)
- Comprehensive coverage of product approvals, pipeline products, and product recalls
Pharmacists’ Forum
- Fast turn-around analysis of pharmacists’ responses to market events and trends
- Pharmacists’ opinions about products from different companies
- Pharmacists’ qualitative inputs on epidemiology data
- Pattern analysis of usage of drugs by physicians
Brand/Product Perception Matrix
- A comprehensive study of customers’ perception and behavior through our inbuilt social connect tool checking the virality and tonality of blogs
- An analysis of overall brand usage and familiarity and brand advocacy distribution (detractor/neutral/familiar)
Please fill in the form below to receive a free copy of the Summary of this Report
Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
| PRODUCT TITLE | PUBLISHED | |
|---|---|---|
|
|
North American Drug Delivery Devices Market The North American Drug Delivery Devices Market was valued at $16 billion in 2013 and expected to be $110 billion by 2018, growing at a CAGR of 8.9%. The report “North American Drug Delivery Devices Market Forecast, 2012-2018“analyzes the market of Drug Delivery Devices by 9 technologies such as oral, transdermal, respiratory, injectable, implantable, transmucosal, nasal, ocular and topical drug delivery devices. The main companies operating in Drug Delivery Devices market and extensively covered in this report are SkyePharma Plc (U.K.), Ypsomed Holding AG (Switzerland), and GSK (U.K.). |
Upcoming |
|
|
European Drug Delivery Devices Market The European Drug Delivery Devices Market was valued at $45 billion in 2013 and expected to be $63 billion by 2018, growing at a CAGR of 8.3%. The report “European Drug Delivery Devices Market Forecast, 2012-2018“analyzes the market of Drug Delivery Devices by 9 technologies such as oral, transdermal, respiratory, injectable, implantable, transmucosal, nasal, ocular and topical drug delivery devices. The main companies operating in Drug Delivery Devices market and extensively covered in this report are SkyePharma Plc (U.K.), Ypsomed Holding AG (Switzerland), and GSK (U.K.). |
Upcoming |
|
|
Asian Drug Delivery Devices Market The Asian Drug Delivery Devices Market was valued at $28 billion in 2013 and expected to be $50 billion by 2018, growing at a CAGR of 12.6%. The report “Asian Drug Delivery Devices Market Forecast, 2012-2018“analyzes the market of Drug Delivery Devices by 9 technologies such as oral, transdermal, respiratory, injectable, implantable, transmucosal, nasal, ocular and topical drug delivery devices. The main companies operating in this market and extensively covered in this report are 3M Company, Alkermes, Baxter International, Inc., Becton, Dickinson & Co., The Dow Chemical Company, Johnson & Johnson, Nektar Therapeutics, SkyePharma PLC,. |
Upcoming |
